Discovery and validation of non-canonical antigens for Hepatocellular Carcinoma immunotherapy
URL https://www.medrxiv.org/content/10.1101/2025.06.08.25328714v1.full.pdf Stage Normal Science Paradigm framing The current paradigm in HCC treatment is immunotherapy, specifically leveraging T-cell recognition of tumor-specific antigens. This preprint operates within this established paradigm. Highlights This research focuses on the discovery and validation of non-canonical antigens (ncORFs) for HCC immunotherapy. It uses established methods like RNA sequencing, mass spectrometry, and